Integrated Wealth Concepts LLC acquired a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 18,408 shares of the company’s stock, valued at approximately $34,000.
A number of other hedge funds also recently bought and sold shares of IBRX. Martingale Asset Management L P increased its holdings in shares of ImmunityBio by 14.8% in the fourth quarter. Martingale Asset Management L P now owns 21,166 shares of the company’s stock valued at $107,000 after purchasing an additional 2,730 shares during the last quarter. Barclays PLC raised its holdings in shares of ImmunityBio by 1.3% during the 4th quarter. Barclays PLC now owns 256,365 shares of the company’s stock worth $1,300,000 after acquiring an additional 3,335 shares during the period. American International Group Inc. boosted its position in shares of ImmunityBio by 11.1% during the 2nd quarter. American International Group Inc. now owns 38,314 shares of the company’s stock valued at $143,000 after acquiring an additional 3,831 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ImmunityBio by 39.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,173 shares of the company’s stock valued at $97,000 after purchasing an additional 5,392 shares during the period. Finally, Point72 Hong Kong Ltd increased its position in ImmunityBio by 2,136.0% during the first quarter. Point72 Hong Kong Ltd now owns 6,149 shares of the company’s stock worth $34,000 after purchasing an additional 5,874 shares during the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.
ImmunityBio Trading Down 8.0 %
IBRX opened at $1.85 on Tuesday. The business’s 50 day moving average price is $2.69 and its 200 day moving average price is $2.76. ImmunityBio, Inc. has a one year low of $1.21 and a one year high of $7.80.
Insider Activity
In related news, Director Michael D. Blaszyk acquired 71,915 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was purchased at an average price of $2.75 per share, with a total value of $197,766.25. Following the transaction, the director now owns 71,915 shares of the company’s stock, valued at approximately $197,766.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other ImmunityBio news, Director John Owen Brennan purchased 25,000 shares of the business’s stock in a transaction on Friday, June 2nd. The shares were bought at an average cost of $2.83 per share, for a total transaction of $70,750.00. Following the completion of the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at $70,750. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael D. Blaszyk acquired 71,915 shares of the stock in a transaction dated Monday, June 5th. The stock was acquired at an average cost of $2.75 per share, with a total value of $197,766.25. Following the purchase, the director now owns 71,915 shares of the company’s stock, valued at approximately $197,766.25. The disclosure for this purchase can be found here. Insiders own 77.63% of the company’s stock.
Analysts Set New Price Targets
Separately, Piper Sandler lowered shares of ImmunityBio from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $10.00 to $4.00 in a report on Friday, May 12th.
Get Our Latest Analysis on ImmunityBio
ImmunityBio Profile
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers.
Featured Stories
- Five stocks we like better than ImmunityBio
- How to Calculate Stock Profit
- 8 Best Meme Stocks to Buy Now
- Conference Calls and Individual Investors
- Is Now The Time To Buy XLF Financial ETF?
- Stock Sentiment Analysis: How it Works
- Three Ways To Play The Rise In Oil Prices
Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX – Free Report).
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
